Antagonisation des héparines et des nouveaux anticoagulants

作者: T. Kortchinsky , B. Vigué , C.M. Samama

DOI: 10.1016/J.ANNFAR.2012.10.034

关键词:

摘要: Even with unfractionated heparin or derivates, the reversal of pharmacologic anticoagulation is crucial in anticoagulated patients developing a life-threatening bleeding scheduled for an emergency procedure. The antagonisation well codified: each milligram protamine sulfate antagonizes 100 IU heparin. Measurement thrombin time reflects anti-IIa effect and has to be monitored immediately 1hour after injection protamine. required dose depends on dosage LMWH administration, although no clinical study supports these data. To date, there effective antidote new anticoagulants (fondaparinux other pentasaccharides, direct inhibitors, anti-Xa inhibitors). Some preliminary studies suggest effectiveness recombinant activated factor VII pentasaccharides not Prothrombin Complex Concentrates oral agents. Therefore, while characteristics could increase comfort improve compliance, their development needs ascertain lack complications need safe antidote.

参考文章(75)
J Van Ryn-McKenna, L Cai, F A Ofosu, J Hirsh, M R Buchanan, Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thrombosis and Haemostasis. ,vol. 63, pp. 271- 274 ,(1990) , 10.1055/S-0038-1645207
P. Sié, C.-M. Samama, A. Godier, N. Rosencher, A. Steib, J.-V. Llau, P. van der Linden, G. Pernod, T. Lecompte, I. Gouin-Thibault, P. Albaladejo, [Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors]. Annales Francaises D Anesthesie Et De Reanimation. ,vol. 30, pp. 645- 650 ,(2011) , 10.1016/J.ANNFAR.2011.06.018
G von der Lippe, L Wikstrom, IM Andersen, T Toftegaard-Nielsen, G Alsjo, J Kyst-Madsen, E Stahle, M Bertrand, E Svensson, GP Eriksson, H Wedel, M Gulin, SY Hassan, H Pilegaard, J Nordrehaug, B Lindvall, TT Nielsen, KA Jacobsson, S Persson, P Abrahamsson, A Holmgren, P Grande, G Lindstrom, E Stahl, T Seim, JE Nordrehaug, JD Nielsen, D Julian, G Setterberg, J Hulting, K Radegran, D Lindblom, M Arbeus, SL Ekstrom, H Saetre, O Geiran, T Jernberg, G Stenport, H Ohlin, H Bylund, G Frostfeldt, I Sjogren, A Rollag, B Andren, R Svedjeholm, T Kellerth, B Svane, L Wallentin, M Janzon, B Lindahl, S Husted, U Naslund, F Kontny, E Logander, E Swahn, B Lagerqvist, K Thygesen, E Diderholm, A Siegbahn, P Venge, M Dellborg, Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators The Lancet. ,vol. 354, pp. 701- 707 ,(1999)
Brian S. Bull, Wilfred M. Huse, Floyd S. Brauer, Ralph A. Korpman, Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 69, pp. 685- 689 ,(1975) , 10.1016/S0022-5223(19)41500-6
Charles Marc Samama, Anne Godier, Nouveaux anticoagulants: premier bilan Sang thrombose vaisseaux. ,vol. 21, pp. 389- 395 ,(2009) , 10.1684/STV.2009.0422
Ola Dahl, Michael Huo, Andreas Kurth, Stefan Hantel, Karin Hermansson, Janet Schnee, Richard Friedman, Bengt Eriksson, , Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): A randomised, double-blind, non-inferiority trial Thrombosis and Haemostasis. ,vol. 105, pp. 721- 729 ,(2011) , 10.1160/TH10-10-0679
Raphael Marlu, Enkelejda Hodaj, Adeline Paris, Pierre Albaladejo, Jean Crackowski, Gilles Pernod, Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thrombosis and Haemostasis. ,vol. 108, pp. 217- 224 ,(2012) , 10.1160/TH12-03-0179
Uwe Nicolay, Heinz-Jürgen Friesen, Martin Reers, Gerhard Dickneite, Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig Thrombosis and Haemostasis. ,vol. 80, pp. 192- 198 ,(1998) , 10.1055/S-0037-1615162
J. I. WEITZ, Factor Xa or thrombin: Is thrombin a better target? Journal of Thrombosis and Haemostasis. ,vol. 5, pp. 65- 67 ,(2007) , 10.1111/J.1538-7836.2007.02552.X